Levodopa

CHEMBL1009 Phase 4 Zugelassen Small molecule

Half-Life

1.5 hours

Bioavailability

—

Protein Binding

—

Molecular Weight

197.2 g/mol

LogP

-2.7

Phase

4

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Molekularmasse

197,1880 g/mol

LogP

-2,70

TPSA

104,00 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Age-Related Macular Degeneration Pain Management Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Generalized Anxiety Disorder Stroke Type 2 Diabetes Major Depressive Disorder Chronic Pain

Arzneimittelklassen

N — N - Nervous System

Wirkmechanismus

Metabolic precursor of dopamine that crosses the BBB.

Pharmacokinetics (PK)

Half-Life 1.5 hours

Pharmacodynamics (PD)

Mechanismus

Metabolic precursor of dopamine that crosses the BBB.

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

InChI

InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

Molecular Formula

C9H11NO4

HBD / HBA

4 / 5

Rotierbare Bindungen

3

Schwere Atome

14

DRD2 (Dopamine D2 Receptor) Agonist

Primary Target

ABCB1 (P-glycoprotein) Substrate

Major Levodopa + Quetiapine

Quetiapine, a D2 receptor antagonist, pharmacodynamically opposes levodopa's dopaminergic effect, worsening Parkinson's disease motor symptoms.

Major Levodopa + Aripiprazole

Aripiprazole acts as a partial D2 agonist/antagonist and can oppose levodopa's dopaminergic therapy, worsening Parkinson's disease symptoms.

Moderate Levodopa + Carbamazepine

Carbamazepine may reduce levodopa efficacy through enzyme induction and pharmacodynamic antagonism, potentially worsening Parkinson's disease control.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A dopamine precursor used as the primary treatment for Parkinson's disease, where it is converted to dopamine in the brain to replace the lost chemical messenger. It is typically combined with carbidopa to enhance its effectiveness and reduce side effects.

Metabolic precursor of dopamine that crosses the BBB.

Key pharmacokinetic parameters for Levodopa: Half-life: 1.5 hours.

Yes, Levodopa is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

ADME Journey →

Related Drugs

Same Drug Class

Acetaminophen Small molecule Aspirin Small molecule Sertraline Small molecule Escitalopram Small molecule

Same Target

Quetiapine Small molecule Aripiprazole Small molecule

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1009. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6047. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Levodopa auf PillFYI

Struktur

Schnelldaten

Class: N - Nervous System
Formel: C9H11NO4
Synonyme: 11

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Levodopa

Therapeutische Bereiche

Arzneimittelklassen

Wirkmechanismus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

Cite this structure

Embed this structure

No side effects recorded

Häufig gestellte Fragen

Related Drugs

Same Drug Class

Same Target

References & Data Sources

Embed This Widget